Alimetry has developed a wearable, non-invasive medical device and app platform for the rapid and detailed diagnosis of a range of gastrointestinal disorders. Their objective measurement approach supersedes traditional “symptoms approach” diagnostics, reducing uncertainties, time, cost, and stress to both patients and clinicians. 

Developed at the University of Auckland’s Bioengineering Institute, Alimetry is built on more than a decade of fundamental research in both clinical and academic settings, led by Professor Greg O’Grady as CEO. The company is working closely with Key Opinion Leaders (KOLs) within the GI field to establish their presence within the market through a record of clinical studies and associated performance excellence.

 Since leaving stealth mode in mid-2021, Alimetry has doubled their IP portfolio and been granted regulatory approval in multiple jurisdictions. They completed an oversubscribed $16.3M Series A capital raise in 2021. The funds raised will support the international market entry for their first product, Gastric Alimetry. Matū is committed to support the operational strategy and governance in the long-term, alongside investment partners Movac, IP Group, and the University of Auckland Inventor’s Fund.